An improved process for the manufacture of 2,3:4,5-bis-O-(l-methylethylidene)-β-D-fructopyranose sulfamate, viz. Topiramate is reported. It consists of subjecting an intermediate of the formula 2,3:4,5-bis-0-(l-methylethylidene)-β-D-fructopyranose to a sulfamoylation reaction with sulfamoyl halide in a suitable solv...
Disclosed herein an improved processes for preparing an amorphous and crystalline forms of 4-acetoxy-2α-benzoyloxy-5β,20-epoxy-1β,7β,10β-trihydroxy-9-oxo-11-taxen-13α-yl(2r,3s)-3-tert-butoxycarbonylamino-3-phenyl-2-hydroxypropionate
The present invention relates to an improved process for the manufacture of 1-[[[(1R)-1-[3-[(1E)-2-(7-chloro-2-quinolinyl) ethenyl] phenyl]-3-[2-(1-hydroxy-1-methylethyl) phenyl] propyl] thio] methyl] cyclopropane acetic acid, sodium salt I, which is known as Montelukast.
The invention relates to an improved process for the manufacture of Methyl-2-(3-(2-(7-chloro-2-quinolinyl)-ethenyl)phenyl)-3-oxopropyl)benzoate II, which is an intermediate in the manufacture of Montelukast sodium of formula I.
The invention describes an improved process for the manufacture of a Flecainide
intermediate viz N-(pyridin-2-ylmethyl)-2,5-bis(2,2,2-trifluoroethoxy) benzamide (II). It consists of reacting 2,5-bis (2,2,2-trifluoroethoxy) benzoic acid with an acid chloride in a solvent mixture in presence of a base at -10 t...
An improved process for the manufacture of 1-[[[(1R)-1-[3-[(1E)-2-(7-chloro-2-quinoliny)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl) phenyl] propyl] thio] methyl] cyclopropane acetic acid, sodium salt [ montelukast sodium(I)]. It consists of converting a vital intermediate 1-(mercaptomethyl)-cyclopropane acetic ac...
Documents
Form MGT-7-06012020_signed
List of share holders, debenture holders;-30122019
Form AOC-4-02122019_signed
Copy of Financial Staements duly authenticated as per section 134 (Including Boards report, auditors report and other documents)-25112019
Directors report as per section 134(3)-25112019
Form DIR-12-20052019_signed
Optional Attachment-(1)-24042019
Notice of resignation;-24042019
Evidence of cessation;-24042019
List of share holders, debenture holders;-26122018
Copy of Financial Staements duly authenticated as per section 134 (Including Boards report, auditors report and other documents)-26122018
Directors report as per section 134(3)-26122018
Form MGT-7-26122018_signed
Form AOC-4-26122018_signed
Form AOC-4-15032018_signed
Form MGT-7-15032018_signed
Copy of Financial Staements duly authenticated as per section 134 (Including Boards report, auditors report and other documents)-08032018
Directors report as per section 134(3)-08032018
List of share holders, debenture holders;-08032018
Statement of Subsidiaries as per section 129 - Form AOC-1-08032018
Form AOC - 4 CFS-08062017_signed
Consolidated Financial statements duly authenticated as per section 134 (Including Boards report, auditors report and other docu-01062017
Form AOC-4-19042017_signed
Form MGT-7-19042017_signed
Statement of Subsidiaries as per section 129 - Form AOC-1-12042017
Copy of Financial Staements duly authenticated as per section 134 (Including Boards report, auditors report and other documents)-12042017
Optional Attachment-(1)-12042017
List of share holders, debenture holders;-12042017